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killerFLIP: a novel lytic peptide specifically inducing
cancer cell death
B Pennarun1, G Gaidos2, O Bucur1, A Tinari3, C Rupasinghe2, T Jin1, R Dewar1, K Song1, MT Santos1, W Malorni3,4, D Mierke2 and R
Khosravi-Far*,1,5
One of the objectives in the development of effective cancer therapy is induction of tumor-selective cell death. Toward this end,
we have identified a small peptide that, when introduced into cells via a TAT cell-delivery system, shows a remarkably potent
cytoxicity in a variety of cancer cell lines and inhibits tumor growth in vivo, whereas sparing normal cells and tissues. This fusion
peptide was named killerFLIP as its sequence was derived from the C-terminal domain of c-FLIP, an anti-apoptotic protein. Using
structure activity analysis, we determined the minimal bioactive core of killerFLIP, namely killerFLIP-E. Structural analysis of
cells using electron microscopy demonstrated that killerFLIP-E triggers cell death accompanied by rapid (within minutes)
plasma membrane permeabilization. Studies of the structure of the active core of killerFLIP (-E) indicated that it possesses
amphiphilic properties and self-assembles into micellar structures in aqueous solution. The biochemical properties of killerFLIP
are comparable to those of cationic lytic peptides, which participate in defense against pathogens and have also demonstrated
anticancer properties. We show that the pro-cell death effects of killerFLIP are independent of its sequence similarity with c-FLIPL
as killerFLIP-induced cell death was largely apoptosis and necroptosis independent. A killerFLIP-E variant containing a
scrambled c-FLIPL motif indeed induced similar cell death, suggesting the importance of the c-FLIPL residues but not of their
sequence. Thus, we report the discovery of a promising synthetic peptide with novel anticancer activity in vitro and in vivo.
Cell Death and Disease (2013) 4, e894; doi:10.1038/cddis.2013.401; published online 31 October 2013
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Despite progress in the last decade, with the introduction of
targeted therapies, refractory and relapsed cancer remains a
leading cause of mortality worldwide. RNA interference, drugs
targeting tumor metabolism and cancer immunotherapy hold
exciting therapeutic potential but have not yet translated into
many clinical successes.1–3 For this reason, there is still an
urgent need for novel strategies to target cancer cells.
The last few years have seen a renewed interest in
therapeutic peptides. Peptides are target selective, easy to
synthesize and possess low toxicity profiles. In the past, the
use of native peptides has been hampered by their inactiva-
tion in serum, sensitivity to enzymatic degradation and rapid
clearance from the bloodstream. However, recent technolo-
gical advances such as the design of stapled peptides,
diastereoisomeric peptides, cyclic peptides and the engineer-
ing of peptides capable of self-assembling into nanostructures
have significantly enhanced their utility by increasing their
bioavailability and stability.4–7 Some recently discovered
peptides act as potent inhibitors and/or induce cell death by
various mechanisms in mammalian cells, including cancer
cells.7–9
Targeting cell death mechanisms in diseases, including
cancer, is a promising treatment option.10 While trying to
identify novel ways to induce cancer cell death, we discovered
a 15-mer peptide READFFWSLCTADMS that presented
some homology to a peptide isolated by phage display
screening and alanine scanning (FWWLXTA).11 Our 15-mer
peptide corresponds to a stretch of amino-acid residues in the
C-terminal domain of the long isoform of c-FLICE-like
inhibitory protein (c-FLIPL).
11 c-FLIPL is one of the three
spliced variants of c-FLIP found at the protein level together
with its short isoform (c-FLIPS) and c-FLIPR.
12 Structurally,
c-FLIPL is similar to procaspase 8. It contains two death
effector domain domains and a caspase-like domain. This
caspase-like domain is replaced by short C-terminal
sequences in FLIPS (26–28 kDa) and c-FLIPR (24 kDa).
12
To study potential effects of our c-FLIPL-derived peptide in
cancer cells, an N-terminal TAT cell delivery sequence was
added to facilitate membrane permeability. Interestingly, our
fusion peptide-induced cell death in Jurkat cells in the
micromolar range, independently of death receptor
stimulation. In this study, we characterized the anticancer
properties of this cell death-inducing peptide named killerFLIP
in cell-based models. The active motif of this peptide was
identified and its mechanism of action determined, namely
apoptosis- and necroptosis-independent plasma membrane
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permeabilization of cancer cells. Effects in a HCT116 human
tumor xenograft model were confirmed. Herein, we report a
novel lytic peptide that specifically induces tumor cell death
and offers promising therapeutic potential.
Results
The c-FLIPL-derived fusion peptide induces cell death in
cancer cells in vitro. We previously discovered a 15-mer
peptide (READFFWSLCTADMS) derived from the b5-strand
of c-FLIPL
11 that may have effects on cell death pathways
(Supplementary Figure 1). When fused with an N-terminal
TAT delivery sequence (YGRKKRRQRRR),13 this novel
peptide, under low serum conditions (0.5–5% of FBS),
induced a concentration-dependent decrease in cell viability
in Jurkat cells, as assessed using an ATP-based assay
(Figure 1a). At 10–15 mM, the fusion peptide but not the
TAT-only peptide-induced cell death inB50% of Jurkat cells,
as measured by Trypan blue exclusion assay using a
Bio-Rad TC10 automated cell counter (Figure 1b). As a
result of its ability to induce cancer cell death, the fusion
peptide was named killerFLIP.
The bioactive core of killerFLIP induces cell death in a
range of tumor cells but not in normal cells. To identify
the active core of killerFLIP, we generated truncated
killerFLIP variants (Figure 2a). All peptides were fused to
an N-terminal TAT to allow cell delivery. The effects of these
variants on cell death were measured in Jurkat cells using
propidium iodide (PI) staining. The most effective variants,
namely killerFLIP-A, -B and -E, induced 47.6%, 62.1% and
70.5% cell death, respectively (Figure 2b, upper right panel).
Both killerFLIP-A and -B contain the killerFLIP-E
subfragment. It follows that the FFWSLCTA domain is
sufficient for the activity of killerFLIP. Loss of the CTA
residues resulted in a concomitant loss of activity as cell
death was only seen in 15.9% of Jurkat cells treated with
killerFLIP-D. This emphasizes the importance of the
C-terminal CTA residues. Yet, these CTA residues them-
selves were not sufficient as killerFLIP-C (CTADMS) did not
induce significant cell death (14.6%). These results were
confirmed using a cell viability assay based on relative
ATP levels in Jurkat cells (Figure 2b, lower right panel).
killerFLIP-A, -B and -E induced robust ATP level inhibition
compared with control (down to 34%, 26% and 10%,
respectively). killerFLIP-D, the killerFLIP-E variant lacking
C-terminal CTA residues, elicited a significantly weaker
decrease in ATP levels compared with killerFLIP-E (52%
versus 10%, Po0.001). These results again indicate that
killerFLIP-E retains the cell death-inducing core of killerFLIP.
Concentration-dependent effects of killerFLIP-E on cell death
were confirmed in Jurkat cells using Annexin V staining, with
an EC50 B10.7 mM (EC50: drug concentration that induces
Annexin V positivity in 50% of the cells; Supplementary
Figure 2). Western blot analysis in Jurkat cells shows that at
early time points (3–6 h), killerFLIP-E treatment-induced
appearance of both the large active fragment of caspase 3
(17/19 kDa) and the large fragment of poly (ADP-ribose)
polymerase 1 (PARP-1; 89 kDa; Figure 2c), both hallmarks of
apoptosis.
The effects of killerFLIP-E on cell death were further tested in
a panel of 14 normal and cancer cell lines (Figure 2d). At 20mM,
killerFLIP-E-induced potent cell death in leukemia, prostate
cancer and colon cancer cells. The effects were particularly
dramatic in K562, MV411 and RS411 leukemia cell lines (7.7%,
10.8% and 10.4% Trypan blue-negative cells, respectively). No
toxicity was observed in epithelial and endothelial cells (HPDE
and HUVEC, respectively), nor in pancreatic cancer and breast
cancer cells. Interestingly, no cross-resistance to killerFLIP-E
was observed in the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL)-resistant PC3-TR cell line compared
with its parental PC3 cell line. Overall, killerFLIP-E exhibited
moderate to robust effects in 8 of 12 cancer cell lines, and weak
effects in two normal cell lines.
killerFLIP-E rapidly induces formation of breaks at the
plasma membrane. We next sought to determine the
effects on killerFLIP-E at the ultrastructural level. To
establish optimal killerFLIP-E treatment duration before
electron microscopy analysis, we first examined its effects
on Jurkat and K562 cells in a time-dependent manner using
Trypan blue exclusion assay. Surprisingly, within 5–15 min
Figure 1 The fusion peptide induces cell death in Jurkat cells. (a) Treatment with fusion peptide decreased cell viability as assessed by relative ATP levels. Jurkat cells
were treated overnight with various concentrations of TAT or fusion peptide before ATP levels quantification (expressed as percentage relative to the control). (b) Treatment
with fusion peptide-induced cell death as assessed by Trypan blue exclusion assay. Jurkat cells were treated overnight with various concentrations of TAT or fusion
peptide before Trypan blue staining and quantification. Data representative of at least two independent experiments performed in triplicate were shown. Values are expressed
as mean (± S.D.)
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killerFLIP-E induced a drastic drop in the percentage of
Trypan blue-negative Jurkat cells (Figure 3a). Following
15-min treatment with 20 mM killerFLIP-E, only 21.8% of
Jurkat cells remained Trypan blue-negative compared with
75.2% of TAT-treated cells. Similar effects were seen in
K562 cells (22.4% versus 83% of TAT-treated cells;
Figure 3b). These results indicate that killerFLIP-E causes
rapid loss in plasma membrane integrity in cancer cells.
As killerFLIP-E-induced cell death within 15 min, Jurkat
cells were treated with TAT and killerFLIP-E for 5 min, and the
early effects on subcellular structures examined using
electron microscopy. In cells treated with TAT, typical T-cell
ultrastructural features, for example, a low nuclear/cytoplas-
mic ratio, were observed (Figure 3c, left panel). However,
dramatic alterations were seen in Jurkat cells treated with
killerFLIP-E (Figure 3c, right panel). Single membrane
Figure 2 killerFLIP-E is the bioactive motif of the fusion peptide. (a) Amino-acid sequences of the five c-FLIPL-derived motifs tested. (b) Jurkat cells were treated with the
killerFLIP variants (15 mM) for 18 h before quantification of cell death with PI staining and flow cytometer analysis (top panel). Values are expressed as mean (±S.D.) of three
independent experiments. *Po0.001 using Student’s t-test for the comparison between TAT-treated and cells treated with the killerFLIP variants. Jurkat cells were treated
with the various peptides (15 mM) for 18 h before ATP quantification (bottom panel). Values are expressed as mean (± S.D.) of four independent experiments. *Po0.05 and
**Po0.005 using Student’s t-test for the comparison between TAT-treated and cells treated with the killerFLIP variants. (c) Western blot analysis showing time-dependent
effects of TAT and killerFLIP-E (both 15mM) on caspase 3 and PARP-1 cleavage in Jurkat cells; *Indicates an aspecific band. Data are representative of three independent
experiments. (d) Effects of 18 h killerFLIP-E treatment (20mM) on cell death as assessed by Trypan blue exclusion assay in a panel of normal and cancer cell lines; *Po0.01
and **Po0.001 (Student’s t-test). Data represent mean (± S.D.) of at least two independent experiments
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(therefore non-autophagic) vesicules were observed, some of
them partly associated with the mitochondria. Mitochondria
exhibited increased electron density with altered cristae and
rarefied matrix. Interestingly, breaks were seen at the plasma
membrane (black and white arrows) while the nucleus was
intact (upper left corner). At later time-points (30 min), Jurkat
cells treated with killerFLIP-E displayed features indicative of
late necrosis (data not shown). We also examined the
effects of killerFLIP-E at the ultrastructural level in MCF7
breast cancer cells, which were mostly resistant to
killerFLIP-E (Figure 2d and Supplementary Figure 3). At
30 min, MCF7 cells treated with killerFLIP-E still exhibited
typical ultrastructural features. Importantly, no plasma
membrane breaks were seen. This indicates that membrane
breaks are only induced in cell lines sensitive to killerFLIP-E-
induced cell death.
killerFLIP-E corresponds to a novel cancer cell lytic
peptide. Cationic antimicrobial peptides (CAPs) are known
to permeabilize cell membranes, including cancer cell
membranes.14,15 CAPs have an amphiphilic structure
because of positively charged residues and a large portion
of hydrophobic residues. The eight arginine (R) and lysine
(K) residues in the TAT domain confer killerFLIP-E a þ 8 net
charge, in line with the net positive charge of CAPs ranging
from þ 2 to þ 916 (Figure 4a). In addition to the proline (P)
residue at the C-terminal of the TAT domain, the c-FLIPL-
derived domain of killerFLIP-E is mostly hydrophobic owing
to the presence of phenylalanine (F), tryptophan (W), leucine
(L) and alanine (A) residues. killerFLIP-E thus possesses the
characteristics of an amphiphilic peptide, and might therefore
form micelles in solution. Using DLS, we confirm that
killerFLIP-E molecules self-assemble in aqueous solution
into micelles, spherical and/or cylindrical structures of a
relatively homogeneous diameter (804±236 nM), whereas
the control peptide TAT does not (Figure 4b).
To investigate the structure–function relationship of
killerFLIP-E, we generated a variant containing a scrambled
c-FLIPL-derived fragment (FALFCTSW). We then tested the
effects of this scrambled killerFLIP-E on cell viability using an
ATP-based assay in Jurkat cells. Treatment with killerFLIP-E
and scrambled killerFLIP-E induced similar decreases in
relative ATP levels compared with vehicle-treated cells
(26.6% and 12.7%, respectively; Figure 4c). This strongly
suggests that the biochemical properties of the amino-acid
residues in killerFLIP-E are more critical than their order in the
C-terminal killerFLIP-E domain.
killerFLIP-E induces cell death in a caspase-independent
and receptor-interacting protein kinase 1 (RIPK1)-
independent manner. c-FLIPL is a critical protein influencing
death receptor-mediated apoptosis.17 c-FLIPL modulates
caspase 8 activation within membrane complexes called
death-inducing signaling complexes comprised of death
receptors and adapter proteins such as Fas-associated
death domain (FADD). killerFLIP-E induced some caspase
3 and PARP-1 cleavage at 3 and 6 h (Figure 2c), indicating
apoptosis activation. Day et al.18 suggested that c-FLIPL
a bJurkat K562
killerFLIP-E
TAT
killerFLIP-E
TAT
c
TAT killer FLIP-E
Figure 3 killerFLIP-E rapidly disrupts plasma membrane integrity and induces ultrastructural alterations in cancer cells. (a) Jurkat and (b) K562 cells were treated with
20mM TAT or killerFLIP-E for the indicated times before Trypan blue exclusion assay. Values expressed as mean (± S.D.). (c) EM micrographs showing differences in Jurkat
cell morphology upon exposure to 20mM TAT (left) and killerFLIP-E (right) for 5 min
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might form an apoptotic inhibitory complex (AIC) with DR5,
FADD and caspase-8 in cancer cells. c-FLIPL knockdown
induced ligand-independent apoptosis in a DR5-, FADD- and
caspase 8-dependent manner. We reasoned that because of
its analogy with c-FLIPL, killerFLIP-E might disrupt recruit-
ment of c-FLIPL to these AICs and thereby activate ligand-
independent apoptosis. We utilized FADD- and caspase 8-
deficient Jurkat cell models to test the importance of some
key proteins found in the AIC for killerFLIP-E sensitivity.
killerFLIP-E treatment induced comparable decreases in cell
viability as assessed by ATP levels in parental (clone A3),
FADD-deficient and caspase 8-deficient Jurkat cells
(IC50B26, 20 and 28 mM, respectively) (IC50: the drug
concentration causing a 50% inhibition in relative ATP levels;
Figure 5a). This suggests that FADD and caspase 8 do not
have a role in killerFLIP-E-induced cell death. To further
analyze the role of caspases, we pre-treated Jurkat cells with
the pancaspase inhibitor zVAD-fmk and tested the effects on
killerFLIP-E sensitivity. Cells were also treated with HGS-
ETR2, an agonistic anti-TRAIL-R2 antibody used as a
positive control for apoptotic cell death. Treatment with
10mM TAT did not induce cell death as measured by Trypan
blue exclusion (Figure 5b). Treatment with 7.5mM killerFLIP-
E induced a decrease in the percentage of cells excluding
Trypan blue compared with TAT, from 78% to 15%.
zVAD-fmk pre-treatment (20 mM) significantly impaired
HGS-ETR2-induced cell death from 11% to 70% Trypan
blue-negative cells (Po0.001). Pre-treating Jurkat cells with
20mM zVAD-fmk is therefore sufficient to prevent caspase-
mediated cell death. However, pre-treatment with 20 mM
(and 50mM) zVAD-fmk did not inhibit the effects of killerFLIP-E
(11% Trypan blue-negative cells in both treatment groups).
These results show that killerFLIP-E-induced cell death is
largely caspase independent.
A caspase-independent pathway termed regulated necro-
sis (or necroptosis) can be activated by death receptors in
conditions under which apoptosis are blocked.19 Necroptosis
activation involves formation of a complex called the necro-
some that consists of RIPK1 and RIPK3. Although the
detection of some caspase 3 cleavage suggested otherwise
(Figure 2c), it could not be excluded that killerFLIP-E might
activate necroptosis. To test this hypothesis, we assessed the
effects of killerFLIP-E in a RIPK1-deficient Jurkat model.
killerFLIP-E induced similar decreases in relative ATP levels
in both parental (clone SVT35) and RIPK1-deficient Jurkat
cells (IC50B9mM; Figure 5c). This shows that the effects of
killerFLIP-E on cell viability are independent of necrosome
formation.
killerFLIP is well tolerated in vivo and inhibits tumor
growth. We next tested the effects of killerFLIP in vivo in a
HCT116 human colon tumor xenograft mouse model.
Animals were injected daily with TAT (1.3 and 5.3 mg/kg) or
killerFLIP (2.0 and 8.0 mg/kg) for 18 days. No significant
variation in body weight was detected in mice treated with
TAT or killerFLIP (Figure 6a). Furthermore, no signs of
toxicity were observed in H&E-stained liver sections of
animals killed after 18 days of treatment with vehicle, TAT
or killerFLIP (Figure 6b). Similar findings were made in
H&E-stained brain, heart, lung and spleen tissue sections
(data not shown). Thus, killerFLIP treatment was generally
well tolerated in mice treated for 18 days.
Figure 4 The hydrophobic profile of killerFLIP-E is more important than its sequence for the effects on cell death. (a) The hydrophobic profiles of TAT and killerFLIP-E
were analyzed. (b) Measurement of TAT and killerFLIP-E particule size using DLS. The mean (± S.D.) is shown (nZ7). (c) killerFLIP-E and scrambled killerFLIP-E had
similar effects on cell death in Jurkat cells as assessed by relative ATP levels. Cells were treated for 18 h with TAT, killerFLIP-E or a scrambled killerFLIP-E before
quantification of the relative ATP levels
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More significantly, tumor growth was strongly inhibited in
mice treated with killerFLIP compared with TAT control
peptide (Figure 7a). Following formalin fixation and paraffin
embedding of the tumors from different treatment groups, a
TUNEL assay was performed. Tumor sections from mice
treated with killerFLIP showed increased positive staining for
TUNEL compared with vehicle and TAT-treated groups
(Figure 7b). Overall, our results show that killerFLIP can
prevent human cancer cell growth in vivo.
Discussion
Here, we show that a fusion peptide comprised of a TAT cell
delivery sequence and a 15-mer domain corresponding to the
b5-strand of c-FLIPL
11 induces cell death in cancer cells
in vitro and prevents tumor growth as single agent in an
established HCT116 human colon tumor xenograft model.
Using truncated variants of this killerFLIP fusion peptide, we
found that the E fragment (FFWSCLTA) constitutes the active
Figure 5 killerFLIP-E induces cell death independently of apoptosis and necroptosis. (a) Effects of TAT or killerFLIP-E in parental Jurkat cells, FADD-deficient
Jurkat cells and caspase 8-deficient Jurkat cells as assessed by ATP levels. The results are expressed as the percentage of ATP signal in treated cells relative to
vehicle-treated controls. Lack of caspase 8 and FADD protein expression in caspase 8-deficient (caspase 8 def.) and FADD-deficient (FADD def.) Jurkat cells was
confirmed by western blot analysis; *Indicates an aspecific band. (b) Effects of pre-treatment with various concentrations of the pancaspase inhibitor zVAD-fmk on cell
death induced by vehicle, TAT (10 mM), killerFLIP-E (7.5 mM) or HGS-ETR2 (1 mg/ml) in Jurkat cells, as assessed by Trypan blue staining and quantification. Cells were
preincubated with zVAD-fmk for 30 min before 17 h treatment with TAT, killerFLIP-E or HGS-ETR2. Data representative of at least three independent experiments.
*Po0.001 using Student’s t-test for the comparison between vehicle-treated groups and cells pre-incubated with zVAD-fmk. (c) Parental Jurkat cells (SVT35) and
RIPK1  / cells were treated with various concentrations of killerFLIP-E or 15 mM TAT before relative ATP level quantification. Data representative of two
independent experiments are shown as mean (± S.D.). Lack of RIPK1 protein expression in RIPK1 deficient (RIPK1 def.) Jurkat cells was confirmed by western blot
analysis
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Figure 6 killerFLIP was well tolerated in mice. (a) Box plots showing weights of experimental animals before and after treatment with the indicated peptides. Four groups of
eight mice each were weighed on the first and last days (day 18) of treatment. Black dots represent mean for each treatment group. (b) Representative liver sections from the
indicated experimental groups of mice stained with H&E
Figure 7 Growth of established HCT116 xenograft is significantly impaired in response to killerFLIP. (a) Mice subcutaneously implanted with HCT116 xenograft were
intraperitoneally administered once per day with the indicated doses of TAT or killerFLIP for 18 days. Tumor size was measured as described in Material and Methods section.
(b) Treatment with killerFLIP-induced cell death in xenograft tumors. Histological analysis of biopsy samples from the mice treated with vehicle, TAT or killerFLIP. Tumor
sections from untreated or mice injected with TAT or killerFLIP for 18 days were stained using TUNEL assay
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motif of the full-length c-FLIPL-derived peptide. Investigating
early events of killerFLIP-E-induced cell death yielded critical
insights into its effects on cancer cells. We established using
Trypan blue exclusion assay and electron microscopy that
killerFLIP-E induces rapid (5–15 min) membrane permeabili-
zation in some cancer cells. killerFLIP-E has an amphiphilic
structure owing to its cationic TAT N-terminal domain and its
c-FLIPL-derived lipophilic C-terminal domain. The cationic cell
entry peptide TAT alone did not induce cell death or cause
breaks in the plasma membrane. An analog of killerFLIP-E
containing a scrambled c-FLIPL-derived domain triggered
similar levels of cell death as killerFLIP-E itself. Thus, our data
indicate that the effects of killerFLIP-E do not depend on the
sequence of its c-FLIP-derived residues but on their hydro-
phobic properties.
The amphiphilic structure of killerFLIP-E is analogous to
that of CAPs. CAPs are components of the innate immune
response that have been identified in every kingdom tested
including bacteria, fungi, plants and animals.15 The major
difference is that the biological activity of the CAPs is
sequence and structure dependent. It is only upon folding
into an alpha-helix, which readily occurs upon interaction with
a membrane, that CAPs present an amphipathic nature, with
one face of the helix very hydrophobic, the other containing
charged cationic residues. Some CAPs, including hybrid and
synthetic CAPs, have been shown to exhibit anticancer
properties. Interestingly, the multidrug resistance mechan-
isms found in cancer cells do not seem to affect the response
to these CAPs. We confirmed this finding in the PC3/PC3-TR
prostate cancer cell model in regard to TRAIL resistance. Two
main models of action of CAPs have been proposed, namely
the ‘barrel-stave’ and the ‘carpet’ model.14,15 These two
models describe an initial electrostatic interaction of the
cationic peptides with the negatively charged cancer cell
membrane. This event is followed by the insertion of the
amphiphilic peptide into the plasma membrane through
hydrophobic and van der Waals interactions, which induce
pore formation.16 In the carpet model, CAPs first align parallel
to the membrane. In the barrel-stave model, CAPs directly
aggregates in the lipid bilayer. In both models, transmem-
brane pores are formed once a critical peptide concentration
is reached. A ‘detergent-like’ model has also been proposed
whereby CAPs intercalate between the phospholipid head
groups and induce fragmentation of the lipid bilayer into
micelle-like structures.14 This model would be consistent with
our data showing that killerFLIP-E itself can form micelles in
aqueous solution. The disruption of the electrochemical
gradient by CAPs results in water and ion flow across the
plasma membrane, which cause swelling and bursting of the
cell.15 Electron microscopy images indeed showed that
killerFLIP-E rapidly induced formation of breaks in the plasma
membrane of killerFLIP-E-sensitive Jurkat cells but not in
resistant MCF7 cells.
killerFLIP-E triggers cell death in a wide panel of cancer cell
lines including leukemia, prostate and colon cancer but not in
normal epithelial and endothelial cells. killerFLIP appeared
well tolerated in mice. The outer leaflet of the plasma
membrane of normal eukaryote cells consists predominantly
of zwitterionic phospholipids, whereas the outer leaflet of
cancer cell membranes is enriched in negatively charged
phospholipids. This difference in charge between normal and
cancer cell plasma membranes is critical for the selectivity of
CAPs.20,21 The increased phosphatidylserine content (3–9%)
of the outer leaflet of the plasma membrane in cancer cells
notably contributes to this negative charge.16 Heparan sulfate
and chondroitin sulfate are two major classes of glycosami-
noglycan side-chains of proteoglycans.22 The sulfate groups
provide a highly negative charge to these proteoglycans.23
Differences in proteoglycan expression pattern have been
observed between normal and cancer cells.24–26 Interestingly,
both lytic peptides and TAT are known to bind heparan
sulfate.27–29 However, it is not clear yet whether binding
facilitates cellular entry or whether it sequesters the peptides
away from the lipid bilayer.
Owing to activation of particular glycotransferases, the
surface of cancer cells is also enriched in acidic components
such as O-glycosylated mucines with increased terminal
sialylation, which contributes to their negative charge.15
Although a2,3-sialic acids have been found at the cell surface
of MCF7 breast cancer cells,30,31 MCF7 cells were resistant to
killerFLIP-E. Selective binding and activity of the CAPs might
not be explained solely by the higher negative charge of the
outer leaflet of the lipid bilayer in cancer cells as some CAPs
can permeabilize both negatively charged membranes and
zwitterionic membranes.5 The number of microvilli has also
been suggested to have a role in sensitivity to CAPs. Cancer
cells are characterized by a large number of microvilli, which
increases their surface area and might increase the amount of
peptide at the cell surface. This would in turn allow reaching
the critical threshold necessary to initiate permeabilization.5
We observed a higher number of microvilli in MCF7 cells
compared with Jurkat cells, suggesting that microvilli might
not have a critical role in killerFLIP-E sensitivity.
It is remarkable that not every type of cancer cell tested in
this study was sensitive to killerFLIP-E. Pancreatic and breast
cancer cells in particular were resistant to killerFLIP-E. We
cannot rule out the possibility that cancer cell growth features
such as anchorage dependence,32 formation of tight endoso-
mal intercellular adhesions33 or scattered monolayers, could
represent key variables in killerFLIP-E susceptibility. Interestingly,
leukemia cell lines, which are typically non-adherent,
represented the most sensitive group of cells in our panel. It
will be critical to determine the nature of the plasma
membrane molecules underlying killerFLIP-E sensitivity in
leukemia, prostate and colon cancer cells.
Although the plasma membrane was the primary compart-
ment affected by killerFLIP-E, dramatic changes were also
observed at the mitochondrial level. The cell entry peptide
TAT is known to target therapeutic cargo to the mitochondrial
membrane.34 This suggests a high affinity of killerFLIP-E for
lipid bilayers, including the mitochondrial membrane. Certain
death stimuli activate the intrinsic pathway of apoptosis by
disrupting the outer mitochondrial membrane, resulting in
release of cytochrome c and other pro-apoptotic proteins.
Cytosolic cytochrome c binds apoptotic-protease-activating
factor 1 within a complex called the apoptosome to activate
caspase-9, in turn leading to activation of effector caspases
such as caspase 3. Caspase 3 cleavage by killerFLIP-E might
therefore be a consequence of outer mitochondrial membrane
permeabilization and subsequent activation of the intrinsic
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pathway of apoptosis.35 Importantly, our data show that
killerFLIP-induced cell death is mostly due to direct plasma
membrane permeabilization, not activation of apoptosis or
necroptosis. Developments in the field of biochemical
engineering such as the design of diastereoisomeric, cyclic
or self-assembling peptides have fueled a renewed interest in
peptides as therapeutics.4–6,9 A phase I dose escalation study
with a lytic peptide (LTX-315) was recently completed in
patients with transdermally accessible tumors (Clinicaltrials.gov
identifier: NCT01058616) and several antimicrobial peptides
recently demonstrated efficacy in phase II/III clinical trials.36
In conclusion, synthetic lytic peptides such as killerFLIP-E that
specifically target the plasma membrane of cancer cells
constitute an exciting class of new anticancer drugs. Our data
support further evaluation of the therapeutic potential of
killerFLIP-E in cancer.
Materials and Methods
Reagents. TAT (YGRKKRRQRRR), killerFLIP (YGRKKRRQRRRREADFF
WSLCTADMS) and its variants were made at Dr. Mierke’s lab at Dartmouth,
NH, USA or purchased from Anaspec (Fremont, CA, USA) and Biomatik
(Cambridge, ON, Canada). Anti-procaspase 3, active caspase-3, PARP and
caspase 8 antibodies were obtained from Cell Signaling Technology (Danvers,
MA, USA). Anti-RIPK1 antibody was purchased from BD Transduction
Laboratories (San Jose, CA, USA). Anti-b-actin was from Sigma-Aldrich
(St. Louis, MO, USA). PI was purchased from Roche (Indianapolis, IN, USA).
The pan-caspase inhibitor Benzyloxycarbonyl-Val-Ala-Asp (OMe)-fluoromethylketone
(zVAD-fmk) was from R&D Systems (Minneapolis, MN, USA). The HGS-ETR2
antibody was a kind gift from Human Genome Sciences (Rockland, MD, USA).
Cell lines. Cells were obtained from the American Type Culture Collection
(Manassas, VA, USA) and maintained at low passage number; lines used were
HPDE, K562, MV411, RS411, LNCAP, MIAPACA, ASPC1, HCT116, HCT115,
MCF7 and MDA-MB-231. Human Umbilical Vein Endothelial Cells (HUVEC) were
obtained from Dr. Jack Lawler (Boston, MA, USA). PC3 and PC3-TR cells were a
gift from Dr. Aria Olumi (Boston, MA, USA). Parental Jurkat cells (A3),
FADD-deficient and caspase 8-deficient Jurkat cells were provided by Dr. John
Blenis (Boston, MA, USA). Parental (SVT35) and RIPK1-deficient Jurkat cells
were a gift from Dr. Brian Seed (Boston, MA, USA). K562, Jurkat, MV411, RS411,
PC3, PC3-TR and LNCAP cells were grown in RPMI supplemented with 10% FBS
and 1.5 mmol/l L-glutamine. MIAPACA, ASPC1, HCT116, HCT115, MCF7 and
MDA231 cells were cultured in DMEM supplemented with 10% FBS and
1.5 mmol/l L-glutamine. HCT116 and HCT115 cells were cultured in McCoy’s
Medium supplemented with 10% FBS and 1.5 mmol/l L-glutamine. HUVEC were
grown in M131 medium (Invitrogen, San Diego, CA, USA) supplemented with 5%
FBS and 1.5 mmol/l L-glutamine. HUVEC cells were grown in dishes and plates
pre-coated for 30 min with 1X Attachment factor from Cascade Biologics
(Invitrogen). HPDE cells were grown in DMEM supplemented with 1X
Keratinocyte-SFM and 1X microvascular growth supplement (Invitrogen). All
growth media included 100 units/ml penicillin and 100mg/ml streptomycin. All cell
lines were maintained at 37 1C in a humidified atmosphere with 5% CO2. All
in vitro treatments in this study were performed in medium containing 0.5% FBS.
Sub-G1 analysis. Cells (4 105/ml) were seeded in 12-well plates before
treatment with TAT or the indicated fusion peptides. Cells were then collected and
washed once in PBS. The cells were resuspended in 400ml PI solution (50 mg/ml,
0.1% sodium citrate and 0.1% Triton X-100) before quantification using a
FACSCalibur flow cytometer and CellQuest software (BD Bioscience, San Jose,
CA, USA).
Western blot analysis. Cell extracts were lysed for 30 min on ice in
radioimmunoprecipitation assay buffer containing 50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (Boston
Bioproducts, Ashland, MA, USA) supplemented with 5 mM EDTA, proteCEASE
(G-Biosciences, St. Louis, MO, USA), Halt phosphate inhibitor cocktail (Pierce,
Rockford, IL, USA) and 1 mM phenylmethylsulfonyl fluoride. Lysates were cleared
at 13 200g for 10 min at 4 1C. Proteins were quantified with the BCA protein
assay (Pierce) and diluted to a concentration of 1 mg/ml in 1 Laemmli’s
SDS-sample buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10%
glycerol, 2% b-mercaptoethanol and 0.005% bromophenol (Boston Bioproducts).
Samples were heated to 95 1C for 3–5 min. Proteins (20–50mg per sample) were
resolved by SDS-PAGE and transferred to polyvinylidene difluoride membranes
(Millipore, Bedford, MA, USA). Nonspecific binding sites were blocked with 5%
nonfat dry milk (Bio-Rad, Hercules, CA, USA) in TBS with 0.05% Tween-20
(Fisher Scientific, Billerica, MA, USA) for 1 h at room temperature. After blocking,
the membranes were incubated with specific antibodies overnight at 4 1C. The
horseradish peroxidase-labeled goat anti-rabbit and rabbit anti-mouse secondary
antibodies were from DAKO (Carpinteria, CA, USA). Chemiluminescence was
detected using the ECL, SuperSignal West Pico, SuperSignal West Femto
(Pierce) or the Lumi-Light Plus Western blotting kit (Roche) according to the
manufacturer’s instructions. Western blot analyses were performed at least three
times.
Electron microscopy. Cells (6 106 per treatment group) were harvested
and centrifuged at 1400 r.p.m. for 10 min. Cell samples were then pre-fixed with
2.5% glutaraldehyde in 0.2 M cacodylate buffer, pH 7.2 for 20 min at room
temperature. Following three washes with 0.2 M cacodylate buffer, post-fixation of
the samples was performed with 1% osmium tetroxide in 0.2 M cacodylate buffer
pH 7.2 for 1 h at room temperature, and the cells washed again in 0.2 M
cacodylate buffer. Cells were then dehydrated through a graded series of ethanol
solutions and embedded in Agar 100 (Agar Scientific, Essex, UK). Ultrathin
sections obtained using a MT-2B ultramicrotome (LKB, Pharmacia, Uppsala,
Sweden) were stained with uranyl acetate-lead citrate and examined with a Philips
208S electron microscope (FEI Corporation, Eindhoven, The Netherlands).
Xenograft tumor model. Inoculation of the human colon cancer HCT116
xenograft tumors was performed as described previously.37 Briefly, HCT116 cells
(1 106) were subcutaneously injected into the right flank of 7–8 weeks old
female nu/nu mice (Charles River Laboratories, Wilmington, MA, USA). After 1
week, mice were randomized in four groups of eight mice and the indicated
peptides were injected every day for 18 days by intraperitoneal injection. Tumor
volume was measured using calipers in two dimensions. Primary tumor growth
was calculated using the formula (width2 length) /2. At day 18, mice were killed
and tumors were taken for immunohistological study. Tissues were preserved in
10% formalin immediately after collection and processed into paraffin-embedded
samples. Evaluation of apoptosis by TUNEL staining on slides was performed at
the Rodent Histopathology Core Laboratory of the Dana-Farber/Harvard Cancer
Center (Boston, MA, USA). Morphological analysis of liver samples was carried
out using H&E staining.
Trypan blue exclusion assay. Cells were cultured in 96-well plate. After
treatment, cells in suspension were collected and mixed with 0.4% Trypan blue
solution (Sigma-Aldrich) at a 1 : 1 ratio. In all, 10 ml of the cell suspension was then
loaded onto TC10 System (Bio-Rad) counting slides and the number of viable cells
quantified on a TC10 automated cell counter (Bio-Rad).
Cell viability assay. Cells were seeded in half-surface 96-well plates, treated
as indicated and ATP concentrations were quantified using CellTiter-Glo reagent
(Promega, Madison, WI, USA) according to the manufacturer’s instructions.
Luminescence was recorded using a Victor 3V plate reader (Perkin Elmer, Boston,
MA, USA).
Annexin V/7-AAD staining. Cells were seeded in 12-well plate and treated
for 18 h before collection. Cells were then stained using the Annexin V-BrdU/FITC
flow kit (BD Biosciences-Pharmingen, San Diego, CA, USA), according to the
manufacturer’s instructions. Stained cells were analyzed on a LSRII flow cytometer
and FACSDiva software (BD Biosciences).
Particle radius of killerFLIP-E by DLS. Particle radius of killerFLIP
micelles were determined using dynamic light scattering (DLS) measurements on
a Dynapro Nanostar Wyatt laser photometer (Wyatt technology Corporation, Santa
Barbara, CA, USA). In all, 60 mM killerFLIP-E dissolved in PBS, pH 7.4 at 25 1C,
was exposed to 901 light scattering for 3 min. All samples were filtered, degassed
and scanned using a 1-mm path length quartz cuvette. DLS data were analyzed
by using the CONTIN method supplied by the manufacturer.
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Statistical analysis. All experiments were performed independently at least
three times, except otherwise indicated. Statistical analyses were performed using
two-tailed Student’s t-tests. P-valueso0.05 were considered significant and
indicated with an asterisk.
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